MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer

Luo,Qifeng; Li,Xiaoyu; Li,Jia; Kong,Xiangjie; Zhang,Junfeng; Chen,Lei; Huang,Yixiang; Fang,Lin

doi:10.3892/ijo.2013.2034

MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer

Authors:
- Qifeng Luo
- Xiaoyu Li
- Jia Li
- Xiangjie Kong
- Junfeng Zhang
- Lei Chen
- Yixiang Huang
- Lin Fang
View Affiliations

Affiliations: Department of General Surgery, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China, Department of Microbiology and Genetic Institute, Paris-Sud 11 University, Paris, France
Published online on: July 23, 2013 https://doi.org/10.3892/ijo.2013.2034
Pages: 1212-1218

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are a small class of non-coding RNAs that are widely dysregulated in various cancers. They act as either oncogenes or tumor suppressor genes in human cancer. The purpose of this study was to examine the expression levels of miR-15a in human breast cancer and its potential role in disease pathogenesis. The expression levels of miR-15a were measured by quantitative polymerase chain reaction (qPCR) in 40 breast cancer specimens and adjacent normal breast tissues. MTT assays, colony formation assays, transwell chamber migration assays, cell cycle and apoptosis assays were used to explore the potential function of miR-15a in MDA-MB-231 human breast cancer cells. Luciferase reporter assays were performed to validate the regulation of a putative target of miR-15a, in corroboration with qPCR and western blot assays. We found that the expression of miR-15a was lower in breast cancer specimens compared with adjacent normal tissues (p<0.05). Overexpression of miR-15a inhibited cellular growth, suppressed migration and arrested cells at the G1 phase, but did not promote cellular apoptosis. Luciferase assays indicated that miR-15a can bind with its putative target site in the 3'-untranslated region (3'-UTR) of CCNE1, suggesting that CCNE1 is a direct target of miR-15a. qPCR and western blot analysis indicated that the overexpression of miR-15a results in the downregulation of CCNE1 at the mRNA and protein levels. Taken together, the upregulation of miR-15a expression causes cellular growth inhibition, suppression of migration and G1 phase arrest by targeting CCNE1. These findings suggest that miR-15a may act as a tumor suppressor gene in breast cancer and that, in the future, it could be used as a therapeutic target for the treatment of breast cancer.

View Figures

View References

1.	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
2.	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
3.	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Chen C-Z: MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Noguchi S, Mori T, Hoshino Y, et al: MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett. 307:211–220. 2011. View Article : Google Scholar : PubMed/NCBI
6.	Pallante P, Visone R, Ferracin M, et al: MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer. 13:497–508. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
8.	Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Shi W, Gerster K, Alajez NM, et al: MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res. 71:2926–2937. 2011. View Article : Google Scholar : PubMed/NCBI
10.	Tang D, Zhang Q, Zhao S, et al: The expression and clinical significance of microRNA-1258 and heparanase in human breast cancer. Clin Biochem. 46:926–932. 2013. View Article : Google Scholar : PubMed/NCBI
11.	Sampath D, Liu C, Vasan K, et al: Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood. 119:1162–1172. 2012. View Article : Google Scholar : PubMed/NCBI
12.	Musumeci M, Coppola V, Addario A, et al: Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene. 30:4231–4242. 2011. View Article : Google Scholar : PubMed/NCBI
13.	Cai C-K, Zhao G-Y, Tian L-Y, et al: miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol Rep. 28:1764–1770. 2012.PubMed/NCBI
14.	Diniz MG, Gomes CC, de Castro WH, et al: miR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors. Cell Oncol. 35:285–291. 2012. View Article : Google Scholar : PubMed/NCBI
15.	Yang J, Cao Y, Sun J and Zhang Y: Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Med Oncol. 27:1114–1118. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Spruck CH, Won KA and Reed SI: Deregulated cyclin E induces chromosome instability. Nature. 401:297–300. 1999. View Article : Google Scholar : PubMed/NCBI
17.	Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K and Bedrosian I: Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat. 115:651–659. 2009. View Article : Google Scholar : PubMed/NCBI
18.	Keyomarsi K, Tucker SL, Buchholz TA, et al: Cyclin E and survival in patients with breast cancer. N Engl J Med. 347:1566–1575. 2002. View Article : Google Scholar : PubMed/NCBI
19.	Sgambato A, Camerini A, Collecchi P, et al: Cyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapy. Cancer Sci. 100:1026–1033. 2009. View Article : Google Scholar
20.	Goretti E, Rolland-Turner M, Leonard F, Zhang L, Wagner DR and Devaux Y: MicroRNA-16 affects key functions of human endothelial progenitor cells. J Leukoc Biol. 93:645–655. 2013. View Article : Google Scholar : PubMed/NCBI
21.	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
22.	Bryan BB, Schnitt SJ and Collins LC: Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 19:617–621. 2006. View Article : Google Scholar : PubMed/NCBI
23.	Ljungberg BJ, Jacobsen J, Rudolfsson SH, Lindh G, Grankvist K and Rasmuson T: Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma. BJU Int. 98:661–667. 2006. View Article : Google Scholar
24.	Tryfonopoulos D, Walsh S, Collins DM, et al: Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol. 22:2234–2240. 2011. View Article : Google Scholar : PubMed/NCBI
25.	Oliveras-Ferraros C, Vazquez-Martin A, Lopez-Bonet E, et al: Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. Int J Oncol. 33:1165–1176. 2008.